- Home
- IDR vs XGN Comparison
IDR vs XGN Comparison
Compare IDR & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- XGN
- Stock Information
- Founded
- IDR 1996
- XGN 2002
- Country
- IDR United States
- XGN United States
- Employees
- IDR N/A
- XGN N/A
- Industry
- IDR Precious Metals
- XGN Medical Specialities
- Sector
- IDR Basic Materials
- XGN Health Care
- Exchange
- IDR Nasdaq
- XGN Nasdaq
- Market Cap
- IDR 154.1M
- XGN 138.3M
- IPO Year
- IDR N/A
- XGN 2019
- Fundamental
- Price
- IDR $13.76
- XGN $7.23
- Analyst Decision
- IDR Strong Buy
- XGN Strong Buy
- Analyst Count
- IDR 1
- XGN 2
- Target Price
- IDR $17.50
- XGN $7.50
- AVG Volume (30 Days)
- IDR 315.9K
- XGN 225.1K
- Earning Date
- IDR 07-29-2025
- XGN 08-04-2025
- Dividend Yield
- IDR N/A
- XGN N/A
- EPS Growth
- IDR 144.40
- XGN N/A
- EPS
- IDR 0.62
- XGN N/A
- Revenue
- IDR $27,144,971.00
- XGN $56,724,000.00
- Revenue This Year
- IDR $9.76
- XGN $19.39
- Revenue Next Year
- IDR N/A
- XGN $13.27
- P/E Ratio
- IDR $22.27
- XGN N/A
- Revenue Growth
- IDR 67.42
- XGN 1.78
- 52 Week Low
- IDR $8.90
- XGN $1.71
- 52 Week High
- IDR $19.75
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- IDR 48.18
- XGN 56.74
- Support Level
- IDR $14.00
- XGN $7.10
- Resistance Level
- IDR $14.79
- XGN $7.95
- Average True Range (ATR)
- IDR 0.62
- XGN 0.51
- MACD
- IDR 0.13
- XGN -0.04
- Stochastic Oscillator
- IDR 43.72
- XGN 46.67
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.